Drug Type Small molecule-drug conjugates |
Synonyms VIP280 |
Target |
Mechanism CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors), cyclin-T1 inhibitors(cyclin T1 inhibitors), αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 17 Apr 2023 |